ANDA 212991, held by Amneal Pharmaceuticals. Dexamethasone; Tobramycin.
As of Nov 21, 2026, ANDA 212991 (Tobramycin and Dexamethasone), held by Amneal Pharmaceuticals, was first approved by FDA on Jul 15, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tobramycin and Dexamethasone0.1%;0.3% · suspension/drops;ophthalmic | Dexamethasone; Tobramycin | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters